Periwinkle
OTHER NAME(S): Common Periwinkle, Earlyflowering, Evergreen, Herbe à la Capucine, Herbe de Fidélité, Lesser Periwinkle, Myrtle, Pervenche Mineure, Small Periwinkle, Vincae Minoris Herba, Violette des Morts, Violette de Serpent, Violette de Sorcier, Wintergreen, Vinca minor, Vincapervinca, Petite Pervenche
Overview
Periwinkle is an herb. The parts that grow above the ground are used to make medicine. Don't confuse periwinkle with Madagascar periwinkle (Catharanthus roseus).
Despite serious safety concerns, people use periwinkle for memory and thinking, diarrhea, vaginal discharge, sore throat, and toothache, but there is no good scientific evidence to support these uses.
Periwinkle can lower blood pressure. It can also help reduce swelling (inflammation) and have a drying (astringent) effect on the tissues.
Periwinkle can lower blood pressure. It can also help reduce swelling (inflammation) and have a drying (astringent) effect on the tissues.
Uses
Insufficient Evidence for
- Tonsillitis.
- Sore throat.
- Intestinal swelling (inflammation).
- Toothache.
- Chest pain.
- Wounds.
- High blood pressure.
- Other conditions.
More evidence is needed to rate the effectiveness of periwinkle for these uses.
Side Effects
When taken by mouth: Periwinkle is UNSAFE. It can cause side effects such as nausea, vomiting, and other stomach and intestinal symptoms. It can also cause nerve, kidney, and liver damage. Large amounts can cause very low blood pressure.
Precautions
When taken by mouth: Periwinkle is UNSAFE. It can cause side effects such as nausea, vomiting, and other stomach and intestinal symptoms. It can also cause nerve, kidney, and liver damage. Large amounts can cause very low blood pressure.
Periwinkle is UNSAFE for anyone to use, but people with certain conditions are especially at risk for harmful side effects.
Pregnancy and breast-feeding: Periwinkle is UNSAFE. Don't use it.
Constipation: Periwinkle has a drying effect on tissues. This means it can make constipation worse. Don't use it.
Low blood pressure: Periwinkle can lower blood pressure. If you already have low blood pressure, using periwinkle can make it drop too low. Don't use it.
Surgery: Periwinkle can lower blood pressure. There is a concern that it might interfere with blood pressure control during and after surgery. Stop using periwinkle at least 2 weeks before a scheduled surgery.
Interactions
Moderate Interaction
Be cautious with this combination
- Medications for high blood pressure (Antihypertensive drugs) interacts with PeriwinklePeriwinkle seems to decrease blood pressure. Taking periwinkle along with medications for high blood pressure might cause your blood pressure to go too low. Some medications for high blood pressure include captopril (Capoten), enalapril (Vasotec), losartan (Cozaar), valsartan (Diovan), diltiazem (Cardizem), Amlodipine (Norvasc), hydrochlorothiazide (HydroDiuril), furosemide (Lasix), and many others.
Dosing
The appropriate dose of periwinkle depends on several factors such as the user's age, health, and several other conditions. At this time there is not enough scientific information to determine an appropriate range of doses for periwinkle. Keep in mind that natural products are not always necessarily safe and dosages can be important. Be sure to follow relevant directions on product labels and consult your pharmacist or physician or other healthcare professional before using.
References
- Blumenthal M, ed. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. Trans. S. Klein. Boston, MA: American Botanical Council, 1998.
- McGuffin M, Hobbs C, Upton R, Goldberg A, eds. American Herbal Products Association's Botanical Safety Handbook. Boca Raton, FL: CRC Press, LLC 1997.
- Ellenhorn MJ, et al. Ellenhorn's Medical Toxicology: Diagnoses and Treatment of Human Poisoning. 2nd ed. Baltimore, MD: Williams & Wilkins, 1997.
- Gruenwald J, Brendler T, Jaenicke C. PDR for Herbal Medicines. 1st ed. Montvale, NJ: Medical Economics Company, Inc., 1998.
- Brinker F. Herb Contraindications and Drug Interactions. 2nd ed. Sandy, OR: Eclectic Medical Publications, 1998.
- Agri Res Svc: Dr. Duke's phytochemical and ethnobotanical databases. http://www.ars-grin.gov/duke (Accessed 3 November 1999).
- The Natural Pharmacist. Vinpocetine. http://www.tnp.com/substance.asp?ID=573. (Accessed 16 December 1999).
- Kidd PM. A review of nutrients and botanicals in the integrative management of cognitive dysfunction. Altern Med Rev 1999;4:144-61..
- Ueda, J. Y., Tezuka, Y., Banskota, A. H., Le, Tran Q., Tran, Q. K., Harimaya, Y., Saiki, I., and Kadota, S. Antiproliferative activity of Vietnamese medicinal plants. Biol.Pharm.Bull. 2002;25(6):753-760.
- Mans, D. R., da Rocha, A. B., and Schwartsmann, G. Anti-cancer drug discovery and development in Brazil: targeted plant collection as a rational strategy to acquire candidate anti-cancer compounds. Oncologist. 2000;5(3):185-198.
- Chamouni, P., Lenain, P., Buchonnet, G., Merle, V., Bourgain, C., Boyer, A., Girault, C., and Czernichow, P. Difficulties in the management of an incomplete form of refractory thrombotic thrombocytopenic purpura, the usefulness of vincristine. Transfus.Sci. 2000;23(2):101-106.
- Karpati, E., Biro, K., and Kukorelli, T. [Investigation of vasoactive agents with indole skeletons at Richter Ltd.]. Acta Pharm.Hung. 2002;72(1):25-36.
- Sikorska, A., Slomkowski, M., Marlanka, K., Konopka, L., and Gorski, T. The use of vinca alkaloids in adult patients with refractory chronic idiopathic thrombocytopenia. Clin.Lab Haematol. 2004;26(6):407-411.
- Pepe, C., Hasan, B., Winton, T. L., Seymour, L., Graham, B., Livingston, R. B., Johnson, D. H., Rigas, J. R., Ding, K., and Shepherd, F. A. Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10. J.Clin.Oncol. 4-20-2007;25(12):1553-1561.
- Nakabayashi, M., Ling, J., Xie, W., Regan, M. M., and Oh, W. K. Response to vinorelbine with or without estramustine as second-line chemotherapy in patients with hormone-refractory prostate cancer. Cancer J. 2007;13(2):125-129.
- Nishii, K., Sakakura, M., Tsukada, T., Ryuu, H., and Katayama, N. Successful treatment with imatinib combined with less intensive chemotherapy (vincristine and dexamethasone) as induction therapy in a very elderly patient with Philadelphia chromosome-positive acute lymphoblastic leukemia. Int.J.Hematol. 2007;85(3):273-274.
- Krainer, M., Tomek, S., Elandt, K., Horak, P., Albrecht, W., Eisenmenger, M., Holtl, W., Schramek, P., Stackl, W., Zielinski, C., and Reibenwein, J. A prospective, open label, randomized phase II trial of weekly docetaxel versus weekly vinorelbine as first line chemotherapy in patients with androgen independent prostate cancer. J.Urol. 2007;177(6):2141-2145.
- Ng, R., Hasan, B., Mittmann, N., Florescu, M., Shepherd, F. A., Ding, K., Butts, C. A., Cormier, Y., Darling, G., Goss, G. D., Inculet, R., Seymour, L., Winton, T. L., Evans, W. K., and Leighl, N. B. Economic analysis of NCIC CTG JBR.10: a randomized trial of adjuvant vinorelbine plus cisplatin compared with observation in early stage non-small-cell lung cancer--a report of the Working Group on Economic Analysis, and the Lung Disease Site Group, National Cancer Institute of Canada Clinical Trials Group. J.Clin.Oncol. 6-1-2007;25(16):2256-2261.
- Hirsh, V., Desjardins, P., Needles, B. M., Rigas, J. R., Jahanzeb, M., Nguyen, L., Zembryki, D., and Leopold, L. H. Oral versus intravenous administration of vinorelbine as a single agent for the first-line treatment of metastatic nonsmall cell lung carcinoma (NSCLC): A randomized phase II trial. Am.J.Clin.Oncol. 2007;30(3):245-251.
- Verma, S., Wong, N. S., Trudeau, M., Joy, A., Mackey, J., Dranitsaris, G., and Clemons, M. Survival differences observed in metastatic breast cancer patients treated with capecitabine when compared with vinorelbine after pretreatment with anthracycline and taxane. Am.J.Clin.Oncol. 2007;30(3):297-302.
- Nomura, T., Maekawa, T., Uchino, H., Miyazaki, T., Miura, Y., Abe, T., Asano, S., Kuriya, S., Nagai, K., Yawata, Y., and . Clinical usefulness of vinca alkaloid slow infusion in the treatment of chronic refractory idiopathic thrombocytopenic purpura: a multicenter cooperative study. Nippon Ketsueki Gakkai Zasshi 1990;53(1):98-104.
- Fenaux, P., Quiquandon, I., Caulier, M. T., Simon, M., Walter, M. P., and Bauters, F. Slow infusions of vinblastine in the treatment of adult idiopathic thrombocytopenic purpura: a report on 43 cases. Blut 1990;60(4):238-241.
- Dekoninck, W. J., Jocquet, P., Jacquy, J., and Henriet, M. Comparative study of the clinical effects of vincamine + glycerol versus glycerol + placebo in the acute phase of stroke. Arzneimittelforschung. 1978;28(9):1654-1657.
- Barnett, C. J., Cullinan, G. J., Gerzon, K., Hoying, R. C., Jones, W. E., Newlon, W. M., Poore, G. A., Robison, R. L., Sweeney, M. J., Todd, G. C., Dyke, R. W., and Nelson, R. L. Structure-activity relationships of dimeric Catharanthus alkaloids. 1. Deacetylvinblastine amide (vindesine) sulfate. J.Med.Chem. 1978;21(1):88-96.
- Cardinali, G. [Place of Vinca rosea alkaloids (Catharanthus roseus) in the treatment of Hodgkin's disease]. Haematologica 1973;53(1):51-64.
- Jacquillat, C. and Weil, M. [Periwinkle alkaloids. Treatment of Hodgkin's disease and leukemia]. Sem.Ther. 1964;40(6):395-400.
- Ahn, Y. S., Byrnes, J. J., Harrington, W. J., Cayer, M. L., Smith, D. S., Brunskill, D. E., and Pall, L. M. The treatment of idiopathic thrombocytopenia with vinblastine-loaded platelets. N.Engl.J.Med. 5-18-1978;298(20):1101-1107.
- Wautier, J. L., Boizard, B., and Caen, J. P. [Transfusion of platelets loaded with periwinkle alkaloids as a treatment for chronic idiopathic thrombocytopenic purpura (author's transl)]. Nouv.Presse Med. 1-20-1979;8(3):185-188.
- Mukhopadhyay, S., El-Sayed, A., Handy, G. A., and Cordell, G. A. Catharanthus alkaloids XXXVII. 16-Epi-Z-isositsirikine, a monomeric indole alkaloid with antineoplastic activity from Catharanthus roseus and Rhazya stricta. J.Nat.Prod. 1983;46(3):409-413.
- Schiavotto, C., Castaman, G., and Rodeghiero, F. Treatment of idiopathic thrombocytopenic purpura (ITP) in patients with refractoriness to or with contraindication for corticosteroids and/or splenectomy with immunosuppressive therapy and danazol. Haematologica 1993;78(6 Suppl 2):29-34.
- Rahmani, R. and Zhou, X. J. Pharmacokinetics and metabolism of vinca alkaloids. Cancer Surv. 1993;17:269-281.
- Gross, Z., Rodriguez, J. J., and Stalnaker, B. L. Vincristine for refractory autoimmune thrombocytopenic purpura in pregnancy. A case report. J.Reprod.Med. 1995;40(10):739-742.
- Ena, J., Garcia, A., and de Mar, Masia M. Vincristine as therapy for idiopathic thrombocytopenic purpura in patients infected with human immunodeficiency virus. Clin.Infect.Dis. 1996;22(5):880-881.
- Fischhof, P. K., Moslinger-Gehmayr, R., Herrmann, W. M., Friedmann, A., and Russmann, D. L. Therapeutic efficacy of vincamine in dementia. Neuropsychobiology 1996;34(1):29-35.
- Bolcskei, H., Szantay, C., Jr., Mak, M., Balazs, M., and Szantay, C. [New antitumor derivatives of vinblastine]. Acta Pharm.Hung. 1998;68(2):87-93.